Biofarm Bucure (RO:BIO) — Market Cap & Net Worth
Market Cap & Net Worth: Biofarm Bucure (BIO)
Biofarm Bucure (RO:BIO) has a market capitalization of $280.56 Million (RON1.22 Billion) as of May 2, 2026. Listed on the RO stock exchange, this Romania-based company holds position #15233 globally and #22 in its home market, demonstrating a -1.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biofarm Bucure's stock price RON1.24 by its total outstanding shares 985367224 (985.37 Million). Analyse Biofarm Bucure cash flow conversion to see how efficiently the company converts income to cash.
Biofarm Bucure Market Cap History: 2015 to 2026
Biofarm Bucure's market capitalization history from 2015 to 2026. Data shows growth from $41.11 Million to $280.56 Million (19.29% CAGR).
Index Memberships
Biofarm Bucure is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Bucharest Plus Index
BETPLUS
|
$56.29 Billion | 0.50% | #15 of 42 |
Weight: Biofarm Bucure's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biofarm Bucure Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biofarm Bucure's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.57x
Biofarm Bucure's market cap is 0.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.82x
Biofarm Bucure's market cap is 1.82 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $64.98 Million | $195.32 Million | $50.88 Million | 0.33x | 1.28x |
| 2020 | $82.76 Million | $216.42 Million | $54.26 Million | 0.38x | 1.53x |
| 2021 | $167.27 Million | $239.04 Million | $60.36 Million | 0.70x | 2.77x |
| 2022 | $128.31 Million | $276.98 Million | $70.92 Million | 0.46x | 1.81x |
| 2023 | $179.26 Million | $280.29 Million | $77.01 Million | 0.64x | 2.33x |
| 2024 | $161.55 Million | $286.77 Million | $74.40 Million | 0.56x | 2.17x |
| 2025 | $183.27 Million | $319.33 Million | $100.82 Million | 0.57x | 1.82x |
Competitor Companies of BIO by Market Capitalization
Companies near Biofarm Bucure in the global market cap rankings as of May 2, 2026.
Key companies related to Biofarm Bucure by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Biofarm Bucure Historical Marketcap From 2015 to 2026
Between 2015 and today, Biofarm Bucure's market cap moved from $41.11 Million to $ 280.56 Million, with a yearly change of 19.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | RON280.56 Million | +53.09% |
| 2025 | RON183.27 Million | +13.45% |
| 2024 | RON161.55 Million | -9.88% |
| 2023 | RON179.26 Million | +39.71% |
| 2022 | RON128.31 Million | -23.29% |
| 2021 | RON167.27 Million | +102.10% |
| 2020 | RON82.76 Million | +27.37% |
| 2019 | RON64.98 Million | +15.16% |
| 2018 | RON56.43 Million | +17.92% |
| 2017 | RON47.85 Million | +14.02% |
| 2016 | RON41.97 Million | +2.09% |
| 2015 | RON41.11 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Biofarm Bucure was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $280.56 Million USD |
| MoneyControl | $280.56 Million USD |
| MarketWatch | $280.56 Million USD |
| marketcap.company | $280.56 Million USD |
| Reuters | $280.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biofarm Bucure
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescr… Read more